I acknowledge that any medical treatment may be associated with adverse side effects. These risks are much more likely with non-compliance with the treatment plan. Testosterone therapy has the potential to elevate my risk for cardiovascular events, including cardiomegaly (enlargement of the heart) and increased blood viscosity, which could lead to significant complications such as stroke. Furthermore, testosterone replacement therapy (TRT), particularly in the absence of enclomiphine, is likely to result in a reduction in sperm count, which may adversely impact my fertility and decrease my likelihood of fathering children in the future. In addition, ongoing testosterone treatment may also influence the production of seminal fluid and could result in a decrease in testicular size, both of which are components of reproductive health. It is imperative to consider these risks carefully in conjunction with the potential benefits of the therapy, as a comprehensive understanding of the side effects is crucial in making well-informed decisions regarding my health and treatment alternatives. The Informed Consent for Testosterone Replacement Therapy requires that the patient provides detailed information, including the types of testosterone products utilized, such as injectable Testosterone Cypionate. This therapy is sanctioned for individuals with primary hypogonadism and hypogonadotrophic hypogonadism, while other applications may be regarded as off-label and carry undefined safety and efficacy profiles. Additionally, contraindications include known hypersensitivities to the drug, prostate cancer, and serious heart, liver, or kidney diseases. Potential risks while unlikely at reasonable TRT dosages encompass, but are not limited to, application site reactions, muscle or nerve injury, blood clots leading to heart attack, pulmonary embolism, or stroke; polycythemia (increased blood count which may require blood draws/donation; exacerbation of congestive heart failure or edema; prostate enlargement; worsening of prostate cancer; worsening of sleep apnea; depression or anxiety; gynecomastia; elevated PSA; elevated cholesterol; mood changes; urinary retention; male pattern hair loss; acne; elevated calcium levels; and potential hepatotoxicity or cancer associated with prolonged high-dose use. Before initiating testosterone treatment, laboratory tests are mandated, including testosterone levels, PSA, blood count (CBC), blood sugar, cholesterol, thyroid function, and calcium levels.
Medications containing testosterone are regulated as controlled substances by the DEA and must be stored securely to prevent unauthorized access. It is recommended that these medications be kept in a locked box, cabinet, or safe. Moreover, it is prohibited by federal regulations to sell, share, or distribute this prescription to individuals for whom it has not been expressly prescribed.
Regarding injectable testosterone formulations, Fenton Medical Center will refrain from administering injections if there are indications that the bottle has been compromised in any manner. Noncompliance with required follow-up appointments and monitoring, including necessary laboratory work, is recommended at the initial 3 months, then every 6-12 months, may result in the termination of therapy. I have comprehensively reviewed the risks and side effects associated with the usage of testosterone-containing products and have had the opportunity to pose questions, all of which have been satisfactorily answered. I hereby consent to the initiation or continuation of treatment involving testosterone-containing products and agree to promptly notify the office should I suspect any adverse reactions or side effects stemming from the treatment.
Patient Signature ________________________________________________
Date ______________/_______________/___________________
The Med Vow 